Adocia SA (LS:A1JTC2) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New shares under shareholder loan agreement Tranche closed: convertible Buyers: Vester Finance (shareholder loan of up to €10 million) | Nov 6, 2026 | |
| Private placement of new ordinary shares Announced: €3M · €2.042 a share · Vester Finance Dealers: Vester Finance Buyers: Olivier Soula (2% of the Company’s share capital following completion of the Capital Increase); Vester Finance (6.9% of the Company’s share capital following completion of the Capital Increase) Insiders: All the directors of the Company, including the chief executive officer, participated in the Capital Increase Use of proceeds: Promote BioChaperone technology to sign partnerships, develop AdoXLong platform towards clinic, and general corporate purposes | Oct 20, 2026 | US$3.36M |
| New shares Tranche closed: raise Buyers: Vester Finance (200,000 new shares issued over the month under the shareholder loan agreement) | Aug 24, 2026 | |
| Shareholder loan repayable in new shares Update: up to €6M Buyers: Vester Finance (shareholder loan of up to €6.0 million) Use of proceeds: Extend cash runway until the beginning of Q2 2027 | Apr 21, 2026 | US$7.05M |
| Private placement of new ordinary shares with share warrants attached (ABSAs) Closed: €10M raised · €7.92 a share · Warrants at €9.11 for 42 months · Stifel Europe Securities SAS and Stifel Europe Limited Paris Branch (Stifel) Dealers: Stifel Europe Securities SAS and Stifel Europe Limited Paris Branch (Stifel) (lead) Buyers: CVI Investments, Inc. (subscribed the whole €10 million; 1,262,626 shares, 6.5% of capital post-offering) Use of proceeds: About 50% for the AdoXLong platform, 30% for BioChaperone industrial-scale manufacturing, 20% for working capital | Dec 4, 2025 | US$11.66M |